Results 101 to 110 of about 27,115 (215)

To eGFR or not to eGFR: here is an intern's answer [PDF]

Kidney International, 2009
openaire   +2 more sources

Nanoparticle-based targeted therapy through EGFR tyrosine kinase inhibitors and their recent advances in lung cancer therapy

Exploration of Medicine
The emergence and subsequent advancement of nanotechnology in recent years have greatly benefited the healthcare sector, particularly in the treatment of cancer. As per study, major fatalities are related to the lung cancer. For many years, oral tyrosine
Priyanka S. Waghmare, Anuruddha R. Chabukswar, Kunal G. Raut, Bhagyashree Gaikwad-Pawar, Swati C. Jagdale   +4 more
doaj   +1 more source

Deep Contrastive Learning for High‐Throughput Prediction of Drug Resistance Mutations from Sequences

Advanced Science, EarlyView.
This study presents DeepMutDTA, a deep learning framework aimed at predicting mutation‐induced changes in protein‐drug interactions and prioritizing variants potentially linked to drug resistance. Trained on large‐scale data, it incorporates SimSiam‐MuTF, a label‐aware contrastive fine‐tuning strategy that encourages separation between WT and MT ...
Xiaowen Hu, Pan Zhang, Shangqian Wu, Hao Sun, Minwei Li, Sophia Tsoka, Zizhang Sheng, Lei Deng   +7 more
wiley   +1 more source

Reporting eGFR [PDF]

Clinical Journal of the American Society of Nephrology, 2008
openaire   +2 more sources

Progress of Microsatellite (GT/CA)n Repeat Polymorphisms in Non-small Cell Lung Cancer

Zhongliu Fangzhi Yanjiu
Non-small cell lung cancer (NSCLC) is the most important histological type of lung cancer. This disease affects a large number of patients, and the prognosis of advanced patients is poor.
YANG Wenjun, FU Yuting, YUAN Yeqin, LIU Da, JIANG Binyuan   +4 more
doaj   +1 more source

Synthetic Toll‐Like Receptors for Control of Innate Immunity With Far‐Red Light

Advanced Science, EarlyView.
Synthetic Toll‐like receptors (TLRs) are engineered by replacing their natural sensing regions with a far‐red‐light‐responsive module from a bacterial phytochrome. These synthetic receptors enable light‐controlled regulation of immune signaling in mammalian cells.
Anna V. Leopold, Vladislav V. Verkhusha
wiley   +1 more source

Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review

Case Reports in Oncology
Introduction: Mutation in Kristin ras sarcoma virus (KRAS) oncogene is the main driver in pancreatic ductal adenocarcinoma (PDAC) and is present in nearly 90% of patients with PDAC.
Juhi Mody, Mandana Kamgar
doaj   +1 more source

Phosphorylated STYK1 Promotes Gemcitabine Resistance via Autophagy‐Mediated Cancer Stemness in Pancreatic Cancer

Advanced Science, EarlyView.
Gemcitabine resistance remains a major challenge in pancreatic ductal adenocarcinoma. This study identifies STYK1 as a key mediator of chemoresistance through autophagy‐dependent maintenance of cancer stemness. Gemcitabine‐activated AMPK phosphorylates STYK1 at Ser91 and Ser304, enhancing autophagy and stemness.
Xueying Dong, Shi Li, Chensong Huang, Xuehong Qian, Jieyu Guo, Yahao Guo, Guifang Wu, Qi Zhang, Hongfei Tan, Yu Han, Rui Zhang, Hao Lyu, Shuai Xiao, Dong Guo, Chaojun Yan, Wenying Qin, Changchun Li, Xing‐Zhen Chen, Ying Zhao, Cefan Zhou, Jingfeng Tang   +20 more
wiley   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source

Selenium Nanoparticles Selectively Target KRAS G13D to Inhibit Colorectal Cancer

Advanced Science, EarlyView.
The mechanisms of SeNPs therapy in cancer treatment, encompass three parallel actions: (1) seleno‐amino acids, key metabolites, upregulate GPX2 expression, thereby inhibiting tumor metastasis via the GPX2‐HIF1α‐VEGF signaling pathway; (2) selenite (SeO32−), an inorganic metabolite, forms hydrogen bonds with amino acid residues 13–17 of the KRAS G13D ...
Xiaoting Liu, Chong Wu, Shiyao Song, Li Ma, Shaoqing Huang, Yuting He, Qinghai Li, Yanzhou Chang, Dan Jiang, Yong Mei, Junchao Cai, Zhenshuang Du, Tianfeng Chen, Weiling He   +13 more
wiley   +1 more source